Downregulation of microRNA-138 enhances the proliferation, migrationand invasion of cholangiocarcinoma cells through the upregulation of RhoC/p-ERK/MMP-2/MMP-9

Oncology Reports

Volumn 29, Issue 5, 2013, Pages 2046-2052

  Wang, Qi ^a   Tang, Huihuan ^a   Yin, Shanshan ^a   Dong, Chao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cholangiocarcinoma; Invasion; microRNA 138; Migration; Proliferation; RhoC

Indexed keywords

GELATINASE A; GELATINASE B; MICRORNA; MICRORNA 138; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN RHOC; RAS PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; UPREGULATION;

CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CHOLANGIOCARCINOMA; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICRORNAS; NEOPLASM INVASIVENESS; RHO GTP-BINDING PROTEINS; UP-REGULATION;

EID: 84876276223     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2304     Document Type: Article

References (43)

1. Shimoda M and Kubota K: Multi-disciplinary treatment for cholangiocellular carcinoma. World J Gastroenterol 13: 1500-1504, 2007. (Pubitemid 46672656)
2. Patel T: Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 3: 33-42, 2006.
3. Reddy SB and Patel T: Current approaches to the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep 8: 30-37, 2006.
4. Singh P and Patel T: Advances in the diagnosis, evaluation and management of cholangiocarcinoma. Curr Opin Gastroenterol 22: 294-299, 2006. (Pubitemid 44090067)
5. Kawahigashi Y, Mishima T, Mizuguchi Y, et al: MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs. J Nippon Med Sch 76: 188-197, 2009.
6. Isomoto H: Epigenetic alterations associated with cholangiocarcinoma (Review). Oncol Rep 22: 227-232, 2009.
7. Chen L, Yan HX, Yang W, et al: The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol 50: 358-369, 2009.
8. Zhong XY, Yu JH, Zhang WG, et al: MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through downregulating farnesoid X receptor expression. Gene 493: 44-51, 2012.
9. Zhang J, Han C and Wu T: MicroRNA-26a promotes cholangiocarcinoma growth by activating â-catenin. Gastroenterology 143: 246-256.e248, 2012.
10. Yamanaka S, Campbell NR, An F, et al: Coordinated effects of microRNA-494 induce G(2)/M arrest in human cholangiocarcinoma. Cell Cycle 11: 2729-2738, 2012.
11. Razumilava N, Bronk SF, Smoot RL, et al: miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology 55: 465-475, 2012.
12. Oishi N, Kumar MR, Roessler S, et al: Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology 56: 1792-1803, 2012.
13. Liu CZ, Liu W, Zheng Y, et al: PTEN and PDCD4 are bona fide targets of microRNA-21 in human cholangiocarcinoma. Chin Med Sci J 27: 65-72, 2012.
14. He Q, Cai L, Shuai L, et al: Ars2 is overexpressed in human cholangiocarcinomas and its depletion increases PTEN and PDCD4 by decreasing MicroRNA-21. Mol Carcinog: Dec 28, 2011 (Epub ahead of print).
15. Selaru FM, Olaru AV, Kan T, et al: MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 49: 1595-1601, 2009.
16. Li B, Han Q, Zhu Y, Yu Y, Wang J and Jiang X: Down-regulation of miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist. FEBS J 279: 2393-2398, 2012.
17. Chen YJ, Luo J, Yang GY, Yang K, Wen SQ and Zou SQ: Mutual regulation between microRNA-373 and methyl-CpG-binding domain protein 2 in hilar cholangiocarcinoma. World J Gastroenterol 18: 3849-3861, 2012.
18. Chen Y, Luo J, Tian R, Sun H and Zou S: miR-373 negatively regulates methyl-CpG-binding domain protein 2 (MBD2) in hilar cholangiocarcinoma. Dig Dis Sci 56: 1693-1701, 2011.
19. Chen Y, Gao W, Luo J, Tian R, Sun H and Zou S: Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar cholangiocarcinoma. Oncol Rep 25: 443-451, 2011.
20. Olaru AV, Ghiaur G, Yamanaka S, et al: MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology 54: 2089-2098, 2011.
21. Meng F, Wehbe-Janek H, Henson R, Smith H and Patel T: Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 27: 378-386, 2008.
22. Lee ST, Chu K, Im WS, et al: Altered microRNA regulation in Huntington's disease models. Exp Neurol 227: 172-179, 2011.
23. Jiang L, Liu X, Kolokythas A, et al: Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int J Cancer 127: 505-512, 2010.
24. Liu X, Chen Z, Yu J, Xia J and Zhou X: MicroRNA profiling and head and neck cancer. Comp Funct Genomics 2009: 837514, 2009.
25. Mitomo S, Maesawa C, Ogasawara S, et al: Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Sci 99: 280-286, 2008. (Pubitemid 351228481)
26. Poliseno L, Haimovic A, Segura MF, et al: Histology-specific microRNA alterations in melanoma. J Invest Dermatol 132: 1860-1868, 2012.
27. Jiang L, Dai Y, Liu X, et al: Identification and experimental validation of G protein alpha inhibiting activity polypeptide 2 (GNAI2) as a microRNA-138 target in tongue squamous cell carcinoma. Hum Genet 129: 189-197, 2011.
28. Wang W, Zhao LJ, Tan YX, Ren H and Qi ZT: MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis 33: 1113-1120, 2012.
29. Liu X, Lv XB, Wang XP, et al: MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene. Cell Cycle 11: 2495-2506, 2012.
30. Clark EA, Golub TR, Lander ES and Hynes RO: Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406: 532-535, 2000. (Pubitemid 30625739)
31. Iiizumi M, Bandyopadhyay S, Pai SK, et al: RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancer. Cancer Res 68: 7613-7620, 2008.
32. Shi Z, Chen ML, He QL and Zeng JH: Antisense RhoC gene suppresses proliferation and invasion capacity of human QBC939 cholangiocarcinoma cells. Hepatobiliary Pancreat Dis Int 6: 516-520, 2007. (Pubitemid 47521168)
33. Arocho A, Chen B, Ladanyi M and Pan Q: Validation of the 2-DeltaDeltaCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts. Diagn Mol Pathol 15: 56-61, 2006.
34. Saadoun S, Papadopoulos MC, Hara-Chikuma M and Verkman AS: Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature 434: 786-792, 2005. (Pubitemid 44739524)
35. Aspenstrom P, Fransson A and Saras J: Rho GTPases have diverse effects on the organization of the actin filament system. Biochem J 377: 327-337, 2004. (Pubitemid 38142188)
36. Ravenhall C, Guida E, Harris T, Koutsoubos V and Stewart A: The importance of ERK activity in the regulation of cyclin D1 levels and DNA synthesis in human cultured airway smooth muscle. Br J Pharmacol 131: 17-28, 2000.
37. Corona G, Deiana M, Incani A, Vauzour D, Dessi MA and Spencer JP: Hydroxytyrosol inhibits the proliferation of human colon adenocarcinoma cells through inhibition of ERK1/2 and cyclin D1. Mol Nutr Food Res 53: 897-903, 2009.
38. Ikoma T, Takahashi T, Nagano S, et al: A definitive role of RhoC in metastasis of orthotopic lung cancer in mice. Clin Cancer Res 10: 1192-1200, 2004. (Pubitemid 38198921)
39. Xue F, Takahara T, Yata Y, et al: Blockade of Rho/Rho-associated coiled coil-forming kinase signaling can prevent progression of hepatocellular carcinoma in matrix metalloproteinase-dependent manner. Hepatol Res 38: 810-817, 2008. (Pubitemid 352015632)
40. van Golen KL, Wu ZF, Qiao XT, Bao LW and Merajver SD: RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 60: 5832-5838, 2000.
41. Blain EJ: Mechanical regulation of matrix metalloproteinases. Front Biosci 12: 507-527, 2007.
42. Ehrenfeld P, Conejeros I, Pavicic MF, et al: Activation of kinin B1 receptor increases the release of metalloproteases-2 and -9 from both estrogen-sensitive and -insensitive breast cancer cells. Cancer Lett 301: 106-118, 2011.
43. Ming J, Liu N, Gu Y, Qiu X and Wang EH: PRL-3 facilitates angiogenesis and metastasis by increasing ERK phosphorylation and up-regulating the levels and activities of Rho-A/C in lung cancer. Pathology 41: 118-126, 2009.